Actively Recruiting
Surufatinib as Neoadjuvant Treatment for Locally Advanced or Metastatic Differentiated Thyroid Cancer
Led by Fudan University · Updated on 2023-08-14
32
Participants Needed
1
Research Sites
156 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Locally advanced thyroid cancer has a wide range of surgery, large trauma and high local recurrence rate. It is one of the main causes of death in patients with thyroid cancer. Therefore, more effective treatments are urgently needed. This study is designed to evaluate the efficacy and safety of the Surufatinib for Locally Advanced Thyroid Cancer.
CONDITIONS
Official Title
Surufatinib as Neoadjuvant Treatment for Locally Advanced or Metastatic Differentiated Thyroid Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Locally advanced or metastatic thyroid cancer confirmed by histology or cytology, including papillary, follicular, poorly differentiated, or differentiated thyroid cancer
- Locally advanced stage with tumor invasion or adhesion to specific organs or structures, AJCC T4 stage, or difficult to achieve R0/R1 resection
- Age between 14 and 75 years
- At least one measurable lesion according to RECIST 1.1
- Eastern Cooperative Oncology Group (ECOG) performance status 0-1
- Expected survival time of at least 12 weeks
- Adequate organ function including specific blood counts and liver and kidney function within defined limits
- For subjects of potential fertility, use of approved contraception during treatment and for 180 days after, with negative serum HCG test before first medication
You will not qualify if you...
- Prior treatment with anti-angiogenic small molecule targeted drugs
- Received other anti-tumor therapy (including chemotherapy, radiotherapy) within 4 weeks before treatment, except TSH suppression
- Allergy to Surufatinib
- History of serious cardiovascular or cerebrovascular diseases
- Tumor invasion of important blood vessels or high risk of fatal bleeding as judged by imaging or researchers
- Uncontrolled hypertension with systolic 65150 mmHg or diastolic 65100 mmHg
- Other malignant tumors within past 5 years except cured basal cell carcinoma of skin or carcinoma in situ of cervix
- Investigator judgement deeming subject unsuitable for study due to clinical or laboratory abnormalities or other reasons
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China, 200032
Actively Recruiting
Research Team
J
Jiaying Chen
CONTACT
Y
Yu Wang
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here